Literature DB >> 4006384

Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment.

B Lund, T L Storm, B Lund, F Melsen, L Mosekilde, R B Andersen, C Egmose, O H Sørensen.   

Abstract

Long-term glucocorticoid treatment might interfere with the vitamin D metabolism. The serum concentrations of 25-OHD were significantly reduced whereas the circulating levels of 1,25-(OH)2D were normal in 50 patients with rheumatoid arthritis on long-term treatment with small doses of prednisone. The bone mineral content of the forearm was significantly reduced, but the degree of bone loss did not correlate with duration of treatment or dose of prednisone given. Quantitative bone histomorphometry was performed in 18 patients. Apart from a significant correlation between serum 25-OHD and the fractional trabecular bone volume, no relationships were observed between bone histomorphometry and vitamin D metabolites or serum iPTH. The results indicate that the bone loss was due to a decreased osteoblastic activity rather than to an impaired vitamin D metabolism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4006384     DOI: 10.1007/bf02032284

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  Corticosteroid osteoporosis.

Authors:  J C Gallagher; J Aaron; A Horsman; R Wilkinson; B E Nordin
Journal:  Clin Endocrinol Metab       Date:  1973-07

2.  Hydrocortisone-induced inhibition of protein synthesis and uridine incorporation in isolated bone cells in vitro.

Authors:  W A Peck; J Brandt; I Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1967-06       Impact factor: 11.205

3.  Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in the Danish population.

Authors:  B Lund; O H Sørensen
Journal:  Scand J Clin Lab Invest       Date:  1979-02       Impact factor: 1.713

4.  Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration.

Authors:  T J Hahn; L R Halstead; S L Teitelbaum; B H Hahn
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

5.  The effect of Prednisolone upon the metabolism and action of 25-hydroxy-and 1,25-dihydroxyvitamin D3.

Authors:  M Carré; O Ayigbedé; L Miravet; H Rasmussen
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

6.  Tetracycline double-labeling of iliac trabecular bone in 41 normal adults.

Authors:  F Melsen; L Mosekilde
Journal:  Calcif Tissue Res       Date:  1978-12-08

7.  Parathyroid hormone and 25-hydroxyvitamin D levels in glucocorticoid-treated patients.

Authors:  D M Slovik; R M Neer; J L Ohman; F C Lowell; M B Clark; G V Segre; J T Potts
Journal:  Clin Endocrinol (Oxf)       Date:  1980-03       Impact factor: 3.478

8.  Total body calcium in rheumatoid arthritis: effects of disease activity and corticosteroid treatment.

Authors:  D M Reid; N S Kennedy; M A Smith; P Tothill; G Nuki
Journal:  Br Med J (Clin Res Ed)       Date:  1982-07-31

9.  Measurement of circulating 1,25-dihydroxyvitamin D in man. Changes in serum concentrations during treatment with 1 alpha-hydroxycholecalciferol.

Authors:  B Lund; B Lund; O H Sørensen
Journal:  Acta Endocrinol (Copenh)       Date:  1979-06

10.  Production, degradation, and circulating levels of 1,25-dihydroxyvitamin D in health and in chronic glucocorticoid excess.

Authors:  E Seeman; R Kumar; G G Hunder; M Scott; H Heath; B L Riggs
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

View more
  8 in total

1.  Osteopenia in the maxillofacial area: a study in sheep.

Authors:  E Veigel; R J Moore; M R Zarrinkalam; D Schulze; S Sauerbier; R Schmelzeisen; P J Voss
Journal:  Osteoporos Int       Date:  2010-05-26       Impact factor: 4.507

2.  Bone histomorphometry in Cushing's syndrome.

Authors:  A Borelli; M O Leite; P H Correa; V Jorgetti; J A Marcondes; J R Batalha; A B Cintra; B L Wajchenberg
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

Review 3.  Complications of corticosteroid therapy.

Authors:  C Talar-Williams; M C Sneller
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

4.  Reduced bone density at completion of chemotherapy for a malignancy.

Authors:  P Arikoski; J Komulainen; P Riikonen; J S Jurvelin; R Voutilainen; H Kröger
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

5.  Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study.

Authors:  P Chavassieux; P Pastoureau; M C Chapuy; P D Delmas; P J Meunier
Journal:  Osteoporos Int       Date:  1993-03       Impact factor: 4.507

Review 6.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

7.  Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids.

Authors:  Jennifer Harrington; Douglas Holmyard; Earl Silverman; Etienne Sochett; Marc Grynpas
Journal:  Pediatr Rheumatol Online J       Date:  2016-11-10       Impact factor: 3.054

8.  Adherence to risk management guidelines for drugs which cause vitamin D deficiency - big data from the Swedish health system.

Authors:  Ola Nordqvist; Ulrika Lönnbom Svensson; Lars Brudin; Pär Wanby; Martin Carlsson
Journal:  Drug Healthc Patient Saf       Date:  2019-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.